https://orcid.org/0000-0003-2427-915X
References
- Chim CS, Lie AK, Chan EY, et al. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. J Hematol Oncol. 2012;5:28.
- Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252–262.
- van de Donk NW, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;64:939–948.
- Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
- Nijhof IS, Groen RW, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21:2802–2810.
- Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Eng J Med. 2012;366:2008–2016.
- Bai Y, Wong KY, Fung TK, et al. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. J Hematol Oncol. 2016;9:107.
- Kumar S, Paiva B, Anderson KC, et al. International myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
- Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
- Yao Q, Bai Y, Orfao A, et al. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. Front Oncol. 2019;9:449.
- Yao Q, Bai Y, Orfao A, et al. Upgraded standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. J Mol Diagn. 2020;22(5):679–684.
- Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181:11–26.
- Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–2076.